Zimmer Biomet Holdings, IncNYSE: ZBH
Health Care · Health Care Equipment
$83.23
+0.97%
Vol: 3.1M
Research Digest
Friday, May 1, 2026
Q1 earnings beat 31% YoY; CFO departing but guidance raised on tech momentum
Zimmer Biomet reported Q1 2026 net sales of $2.087B (+9.3% YoY) and net income of $238M ($1.22 EPS, +31% YoY). CFO Suketu Upadhyay departed effective April 28 to join Incyte, with Controller Paul Stellato stepping in as interim CFO. Despite the leadership transition, management raised adjusted EPS and free cash flow guidance citing strong technology sales momentum (double-digit growth) and new product launches. Truist reaffirmed Hold rating with $92 PT (down from $98). Stock experienced volatility on CFO exit news.
Previous Market Intelligence
13 daysApr 30Zimmer Biomet beats Q1 earnings but stock plunges 10.5% on CFO departureNegative▶
Zimmer Biomet reported Q1 EPS of $2.09 beating estimates of $1.87, with revenue of $2.087B up 9.3% YoY. The company raised full-year EPS guidance to $8.40-$8.55 and FCF growth guidance to 9-11%. However, CFO Suketu Upadhyay departed for a new opportunity on April 28, damping investor sentiment despite strong operating results. Multiple analysts including Stifel and Truist cut price targets in response.
Apr 16First outpatient robotic shoulder replacement performed; Q1 earnings expected April 28 with 2.8% EPS growthPositive▶
Zimmer Biomet achieved a clinical milestone on April 9, 2026: first complete robotic-assisted shoulder replacement in an ambulatory surgery center performed at Summit Health using ROSA Robotics Platform. Q1 earnings webcast set for April 28 at 8:30 a.m. ET. Analyst consensus: 11 Buy, 15 Hold, 2 Sell with $110 median PT.
Apr 15Zimmer Biomet ROSA Knee receives FDA 510(k) clearance; first robotic shoulder replacement at outpatient center.Positive▶
Zimmer Biomet achieved FDA 510(k) clearance for enhanced ROSA Knee robotic technology and FDA Breakthrough Device Designation for iodine-treated total hip replacement. Summit Health performed the nation's first complete robotic-assisted shoulder replacement in a freestanding ambulatory surgery center using ROSA. Q1 2026 earnings call scheduled April 28. Average analyst price target is $102.14 with Hold consensus.
Apr 14Zimmer Biomet appoints new science/technology officer and achieves milestone with first outpatient robotic shoulder replacement.Positive▶
Zimmer Biomet announced the appointment of Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer effective April 14, overseeing AI, robotics, smart implants, and data management. Summit Health performed the nation's first robotic-assisted shoulder replacement in an outpatient surgery center using Zimmer's ROSA platform. Q1 2026 earnings expected April 28 with 2.8% EPS growth.
Apr 13Zimmer Biomet appointed new Chief Science, Technology and Medical Affairs Officer ahead of Q1 earnings April 28.Neutral▶
Zimmer Biomet announced Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer effective April 14, overseeing global technology portfolio including AI, robotics, and smart implants. Company declared $0.24 Q1 dividend. Q1 2026 earnings webcast scheduled April 28.
Apr 10Zimmer Biomet appoints Dr. Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer effective April 14.Neutral▶
Zimmer Biomet announced appointment of Dr. Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. Company scheduled Q1 2026 earnings webcast for April 28 at 8:30 a.m. ET. Analyst consensus: 11 Buy, 15 Hold, 2 Sell ratings with median price target of $110.
Apr 9Zimmer Biomet appoints Vigdorchik as Chief Science Officer; Q2 net sales up 7% YoYMixed▶
Zimmer Biomet appointed Dr. Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer effective April 14, overseeing AI, robotics, smart implants, and medical education strategy. Q2 2025 net sales of $2.077B (up 7.0% YoY) with diluted EPS $0.77 and adjusted EPS $2.07 (+3.0% YoY). Stock valuation estimated $103 vs. $91.40 current (modestly undervalued). Robotics platforms (ROSA, Monogram) drive premium product adoption and recurring revenue. Oak Thistle boosted stake 78.8%; Matrix Asset Advisors reduced 75%. BTIG downgraded to Neutral March 2026; stock down 20.90% YoY.
Apr 8Zimmer Biomet appoints Vigdorchik as Chief Science, Technology and Medical Affairs OfficerNeutral▶
Zimmer Biomet appointed Dr. Jonathan Vigdorchik as Chief Science Officer effective April 14, 2026. Q4 2024 net sales: $2.023B (+4.3% YoY), full year 2024: $7.679B (+3.8% YoY). Stock down 5.87% weekly, down 20.90% YoY. Mixed analyst sentiment on growth prospects.
Apr 7Zimmer Biomet receives ROSA Knee robotic tech clearance, transitions to direct sales model.Neutral▶
Zimmer Biomet (ZBH) delivered on 2025 targets with revenue acceleration and Q4 organic growth. Adjusted EPS reached $8.20 (+2.5% YoY); generated $1.172B free cash flow. Board approved $1.5B repurchase authorization. FDA cleared enhanced ROSA Knee Robotic Technology. Company transitioning to direct/specialized U.S. sales. Stock down 20.9% YoY. Analysts rate 'Hold' with PT $105.17 (+12.75% upside).
Apr 6Zimmer Biomet Q3 EPS beat but missed sales; dividend payment April 30.Neutral▶
Zimmer Biomet reported Q3 adjusted EPS of $1.90 beating estimates but missed quarterly sales and lowered full-year organic revenue guidance. Quarterly dividend of $0.24 payable April 30, 2026. FY2026 guidance: $8.30-$8.45 EPS. Medical device company navigates competitive headwinds with average analyst Hold rating.
Apr 3No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 2No significant overnight updatesNeutral▶
Zimmer Biomet received three Healthcare Asia Medtech Awards 2026 recognition. Q4 2025 earnings showed adjusted EPS of $2.42 and net sales of $2.24B, both ahead of analyst expectations. 2026 guidance calls for revenue growth of 2.5-4.5% and adjusted EPS of $8.30-$8.45. BTIG downgraded to Neutral from Buy on March 23, 2026.
Apr 1Zimmer Biomet downgraded to Neutral from Buy at BTIG; stock near 52-week lows.Negative▶
Zimmer Biomet was downgraded to Neutral from Buy at BTIG. The company announced a quarterly dividend of $0.24 with ex-date March 31. Stock performance remained weak with -20.90% decline over the last year.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ZBHZIMMER | $83.23 | +0.97% | -9.4% | 9.2x | 0.61 | $16.0B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.